Women with OSA have higher chances of having metabolic syndrome than men: effect of gender on syndrome Z in cross sectional study

Study objectives: This study was done to find out prevalence of Metabolic syndrome (MS) in patients with Obstructive Sleep Apnea (OSA) and whether there is any difference in prevalence of syndrome Z in male and female. Methodology: All consecutive diagnosed patients with OSA between June 2015 and Oct 2019 were screened for metabolic syndrome and factors associated with metabolic syndrome in OSA were analyzed. Results: During study period, 502 patients (357 males; 145 females) were diagnosed with OSA. Mean age was 51.88 +/- 12.18 years (females and males:55.91 +/- 9.74 and 50.24 +/- 12.70 years, respectively). Mean BMI was 31.60 +/- 11.09 kg/m(2) (female: 35.29 +/- 7.19 and male: 30.1 +/- 12.0 kg/m(2)) (p < 0.001). Mean AHI was 62.67 +/- 35.22. Mild, moderate and severe category of OSA constituted 7.3%, 15.3% and 77.4% respectively. MS was found in 72.7% (365 out of 502) individuals with OSA. MS was found in 75.8%, 68.4 and 48.7% in severe, moderate and mild OSA patients respectively (p < 0.001). Females OSA patients had significantly high percentage (88.27%) of metabolic syndrome compared to males OSA patients (66.38%) {p < 0.001}. Female patients with SZ had higher metabolic score (p = 0.019) and were older (p < 0.001). Conclusion: Metabolic syndrome is highly prevalent in OSA population (72.7%) and is much more common in female OSA patients (88%) than males OSA (68%). All OSA patients should be screened for MS so that early intervention can be done in these patients so as to prevent cardiovascular complications. (C) 2021 Elsevier B.V. All rights reserved.

Automated summary

This study aimed to investigate the prevalence of Metabolic syndrome (MS) in patients with Obstructive Sleep Apnea (OSA) and found that MS was highly prevalent in the OSA population at 72.7%, with a higher prevalence of MS in female OSA patients (88%) compared to males (68%). Screening for MS in all OSA patients is recommended for early intervention to prevent cardiovascular complications.